Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery |
| |
| Affiliation: | 1. Department of Medical Oncology, Rotterdam Cancer Institute, P.O. Box 5201, 3008 AE Rotterdam, The Netherlands;2. EORTC Data Center, Brussels, Belgium;3. University Hospital, Groningen, The Netherlands;4. Netherlands Cancer Institute, Amsterdam, The Netherlands;5. Western Infirmary, Glasgow, U.K.;6. Cookridge Hospital, Leeds, U.K.;7. University Hospital, Leiden, The Netherlands;8. University Hospital, Antwerp, Belgium;9. Free University Hospital, Amsterdam, The Netherlands;10. University Hospital, Utrecht, The Netherlands;1. Department of Urology, University of Duesseldorf, Medical Faculty, Heinrich-Heine-University, Moorenstr. 5, Duesseldorf 40225, Germany;2. Department of Urology, Urological Research Lab, Translational Urooncology, University of Duesseldorf, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany;1. Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana;2. Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts;3. Department of Pathology, Warren Alpert Medical School of Brown University, Lifespan Academic Medical Center, Providence, Rhode Island;1. Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA;2. Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA;3. Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA;4. Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA;5. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA;6. Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA;7. Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA;8. Department of Medicine, University of California at San Francisco, San Francisco, CA 94143, USA;9. Department of Radiation Oncology, University of California at San Francisco, San Francisco, CA 94143, USA;10. Department of Urology, University of California at San Francisco, San Francisco, CA 94143, USA;11. Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA 94143, USA;12. Department of Medicine, University of Washington, Seattle, WA 98109, USA;13. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA;14. Cancer Biomarkers Team, Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK;15. Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, London SM2 5NG, UK;16. Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA;17. Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, WA 98109, USA;18. Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA;19. Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA;1. Department of Neurosciences, Section of Human Anatomy, University of Padova, Via Aristide Gabelli 65, 35127, Padova, Italy;2. Department of Cardiac, Thoracic and Vascular Science and Public Health, University of Padova, Via Nicolò Giustiniani 2, 35128, Padova, Italy;3. L.i.f.e.L.a.b. Program, Consorzio per la Ricerca Sanitaria (CORIS), Veneto Region, Via Nicolò Giustiniani 2, 35128, Padova, Italy;4. Plastic and Reconstructive Surgery Unit, University of Padova, Via Nicolò Giustiniani 2, 35128, Padova, Italy;5. Department of Civil, Environmental and Architectural Engineering University of Padova, Via Francesco Marzolo 9, 35131, Padova, Italy;6. Department of Industrial Engineering University of Padova, Via Gradenigo 6/a, 35131, Padova, Italy |
| |
| Abstract: | From 1979 to 1983 the EORTC GU Group treated 239 patients with disseminated non-seminomatous testicular cancer with combination chemotherapy comprising cisplatin, vinblastine and bleomycin in a prospectively controlled trial. The protocol required complete resection of residual masses after induction chemotherapy, provided that serum tumour markers were normal. 102 patients were operated on. 27 patients had mature teratoma (teratoma differentiated) in the resected specimens and 23 had viable cancer. Follow-up data were available for 26 and 22 of these patients, respectively. 23 of 26 patients (88%) with mature teratoma are alive and disease free after a follow-up of 53–110 months (median 92 months). 3 patients developed progressive disease; 1 died. A peculiar case of growing mature teratoma on the forearm is described. 13 of 22 patients (59%) with residual carcinoma are alive and disease free after a follow-up of 74–112 months (median 95 months). The prognosis of patients with carcinoma is shown to be correlated with the completeness of surgery, which in turn is correlated with the initial tumour mass before chemotherapy. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
